Skip to main content
Top
Published in: Rheumatology International 5/2012

01-05-2012 | Case Report

Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome

Authors: Bum-Su Choung, Wan-Hee Yoo

Published in: Rheumatology International | Issue 5/2012

Login to get access

Abstract

Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We report here a rare case of patient with primary SS who developed pancytopenia with severe thrombocytopenia as an initial manifestation and successfully treated with IV immunoglobulin (IVIG). The present case suggests that pancytopenia with severe thrombocytopenia can be a difficult-to-treat abnormality, and initial manifestation of primary SS and IVIG might be an effective treatment for severe thrombocytopenia refractory to high-dose steroid in primary SS.
Literature
1.
go back to reference Moutsopoulos HM, Chused TM, Mann DL, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI (1980) Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med 92(2):212–226PubMed Moutsopoulos HM, Chused TM, Mann DL, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI (1980) Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med 92(2):212–226PubMed
2.
go back to reference Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892PubMed Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892PubMed
3.
go back to reference Asmussen K, Andersen V, Bendixen G, Schiødt M, Oxholm P (1996) A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med 239(6):475–482PubMedCrossRef Asmussen K, Andersen V, Bendixen G, Schiødt M, Oxholm P (1996) A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med 239(6):475–482PubMedCrossRef
4.
go back to reference Seki T, Kiyosawa K, Monno S, Imai Y, Furukawa K, Kumazawa S, Ota M, Saito H, Furuta S, Nakahata T (1993) Cell-mediated immune-pancytopenia complicating primary Sjögren’s syndrome. Am J Hematol 43(3):221–225PubMedCrossRef Seki T, Kiyosawa K, Monno S, Imai Y, Furukawa K, Kumazawa S, Ota M, Saito H, Furuta S, Nakahata T (1993) Cell-mediated immune-pancytopenia complicating primary Sjögren’s syndrome. Am J Hematol 43(3):221–225PubMedCrossRef
5.
go back to reference Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR (1985) Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 59(2):227–230PubMedCrossRef Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR (1985) Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 59(2):227–230PubMedCrossRef
6.
go back to reference Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A (1992) Haematological manifestations of primary Sjögren’s syndrome: a clinicopathological study. Q J Med 83(303):547–554PubMed Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A (1992) Haematological manifestations of primary Sjögren’s syndrome: a clinicopathological study. Q J Med 83(303):547–554PubMed
7.
go back to reference Lamour A, Le Corre R, Pennec YL, Cartron J, Youinou P (1995) Heterogeneity of neutrophil antibodies in patients with primary Sjögren’s syndrome. Blood 86(9):3553–3559PubMed Lamour A, Le Corre R, Pennec YL, Cartron J, Youinou P (1995) Heterogeneity of neutrophil antibodies in patients with primary Sjögren’s syndrome. Blood 86(9):3553–3559PubMed
8.
go back to reference Henriksson G, Manthorpe R, Bredberg A (2000) Antibodies to CD4 in primary Sjögren’s syndrome. Rheumatology (Oxford) 39(2):142–147CrossRef Henriksson G, Manthorpe R, Bredberg A (2000) Antibodies to CD4 in primary Sjögren’s syndrome. Rheumatology (Oxford) 39(2):142–147CrossRef
9.
go back to reference Fox RI, Howell FV, Bone RC, Michelson P (1984) Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 14(2):77–105PubMedCrossRef Fox RI, Howell FV, Bone RC, Michelson P (1984) Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 14(2):77–105PubMedCrossRef
10.
go back to reference Aoki A, Ohno S, Ueda A, Ideguchi H, Ohkubo T, Hagiwara E, Shirai A, Oketani M, Nagaoka S, Senuma A, Ohota S, Matsunaga K, Ishigatsubo Y (2000) Hematological abnormalities of primary Sjogren’s syndrome. Nihon Rinsho Meneki Gakkai Kaishi 23(2):124–128PubMedCrossRef Aoki A, Ohno S, Ueda A, Ideguchi H, Ohkubo T, Hagiwara E, Shirai A, Oketani M, Nagaoka S, Senuma A, Ohota S, Matsunaga K, Ishigatsubo Y (2000) Hematological abnormalities of primary Sjogren’s syndrome. Nihon Rinsho Meneki Gakkai Kaishi 23(2):124–128PubMedCrossRef
11.
go back to reference Sugai S, Tachibana J, Shimizu S, Konda S (1989) Thrombocytopenia in patients with Sjögren’s syndrome. Arthritis Rheum 32(2):234–235PubMedCrossRef Sugai S, Tachibana J, Shimizu S, Konda S (1989) Thrombocytopenia in patients with Sjögren’s syndrome. Arthritis Rheum 32(2):234–235PubMedCrossRef
12.
go back to reference Schattner A, Friedman J, Klepfish A, Berrebi A (2000) Immune cytopenias as the presenting finding in primary Sjögren’s syndrome. QJM 93(12):825–829PubMedCrossRef Schattner A, Friedman J, Klepfish A, Berrebi A (2000) Immune cytopenias as the presenting finding in primary Sjögren’s syndrome. QJM 93(12):825–829PubMedCrossRef
13.
go back to reference Kamimura T, Sato H, Iwamoto M, Nara H, Torikoe K, Masuyama J, Okazaki H, Minota S (2005) Sjögren’s syndrome associated with chronic hepatitis C, severe thrombocytopenia, hypertrophic cardiomyopathy, and diabetes mellitus. Intern Med 44(6):657–661PubMedCrossRef Kamimura T, Sato H, Iwamoto M, Nara H, Torikoe K, Masuyama J, Okazaki H, Minota S (2005) Sjögren’s syndrome associated with chronic hepatitis C, severe thrombocytopenia, hypertrophic cardiomyopathy, and diabetes mellitus. Intern Med 44(6):657–661PubMedCrossRef
14.
go back to reference Haro T, Shimoike E, Horiuchi T, Maruyama T, Niho Y (2000) Severe thrombocytopenia caused by digitoxin intoxication in a patient with heart failure associated with Sjögren’s syndrome. Jpn Circ J 64(4):309–311PubMedCrossRef Haro T, Shimoike E, Horiuchi T, Maruyama T, Niho Y (2000) Severe thrombocytopenia caused by digitoxin intoxication in a patient with heart failure associated with Sjögren’s syndrome. Jpn Circ J 64(4):309–311PubMedCrossRef
15.
go back to reference Pyne D, Ehrenstein M, Morris V (2002) The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 41(4):367–374CrossRef Pyne D, Ehrenstein M, Morris V (2002) The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 41(4):367–374CrossRef
16.
go back to reference Durez P, Tourne L, Feremans W, Mascart-Lemone F, Heenen M, Appelboom T (1998) Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren’s syndrome. J Rheumatol 25(5):1032–1033PubMed Durez P, Tourne L, Feremans W, Mascart-Lemone F, Heenen M, Appelboom T (1998) Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren’s syndrome. J Rheumatol 25(5):1032–1033PubMed
17.
go back to reference Mochizuki H, Kamakura K, Masaki T, Hirata A, Nakamura R, Motoyoshi K (2002) Motor dominant neuropathy in Sjogren’s syndrome: report of two cases. Intern Med 41(2):142–146PubMedCrossRef Mochizuki H, Kamakura K, Masaki T, Hirata A, Nakamura R, Motoyoshi K (2002) Motor dominant neuropathy in Sjogren’s syndrome: report of two cases. Intern Med 41(2):142–146PubMedCrossRef
18.
go back to reference Dupond JL, Gil H, de Wazieres B (1999) Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren’s syndrome. Am J Med 106(1):125PubMed Dupond JL, Gil H, de Wazieres B (1999) Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren’s syndrome. Am J Med 106(1):125PubMed
19.
go back to reference Molina JA, Benito-Leon J, Bermejo F, Jimenez-Jimenez FJ, Olivan J (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjogren’s syndrome. J Neurol Neurosurg Psychiatry 60(6):699PubMedCrossRef Molina JA, Benito-Leon J, Bermejo F, Jimenez-Jimenez FJ, Olivan J (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjogren’s syndrome. J Neurol Neurosurg Psychiatry 60(6):699PubMedCrossRef
20.
go back to reference Canhao H, Fonseca JE, Rosa A (2000) Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren’s syndrome. J Rheumatol 27(4):1102–1103PubMed Canhao H, Fonseca JE, Rosa A (2000) Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren’s syndrome. J Rheumatol 27(4):1102–1103PubMed
Metadata
Title
Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome
Authors
Bum-Su Choung
Wan-Hee Yoo
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1395-4

Other articles of this Issue 5/2012

Rheumatology International 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine